FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients with Locally Advanced Unresectable or Metastatic HER2-positive Gastric Cancer
Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test